Cargando…

The HPLC assay of concentration of azithromycin from two different manufacturers in gingival crevicular fluid (GCF)

BACKGROUND: Azithromycin (AZM) is used in periodontal infections. The present study compared gingival crevicular fluid concentration of azithromycin of two pharmaceutical companies through the HPLC method. METHODS: Two groups (n=15) of healthy volunteers participated in this study. The first group r...

Descripción completa

Detalles Bibliográficos
Autores principales: Khosravi-Samani, Mahmoud, Dehshiri, Khashayar, Kazemi, Sohrab, Shiran, Mohamadreza, Mohgadamnia, Ali-Akbar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Babol University of Medical Sciences 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153517/
https://www.ncbi.nlm.nih.gov/pubmed/27999643
_version_ 1782474709036695552
author Khosravi-Samani, Mahmoud
Dehshiri, Khashayar
Kazemi, Sohrab
Shiran, Mohamadreza
Mohgadamnia, Ali-Akbar
author_facet Khosravi-Samani, Mahmoud
Dehshiri, Khashayar
Kazemi, Sohrab
Shiran, Mohamadreza
Mohgadamnia, Ali-Akbar
author_sort Khosravi-Samani, Mahmoud
collection PubMed
description BACKGROUND: Azithromycin (AZM) is used in periodontal infections. The present study compared gingival crevicular fluid concentration of azithromycin of two pharmaceutical companies through the HPLC method. METHODS: Two groups (n=15) of healthy volunteers participated in this study. The first group received an imported azithromycin (ImAZM) tablet (250 mg, PO) and the second group received an azithromycin tablet (250 mg PO) manufactured by an Iranian pharmaceutical company (IrAZM). Intrasulcular paper points (#30) were used in inter-proximal areas of molars and canines to collect gingival crevicular fluid samples at 6, 12, 36, 84 and 156 hours after drug administration. RESULTS: The maximum concentration of AZM in gingival crevicular fluid was detected in each group 36 hour after administration. The concentration levels for the participants receiving ImAZM and IrAZM were 14.38±5.75 and 12.64±3.53 ng/mL, respectively. The pharmacokinetic (PK) modeling data showed half-life of AZM was 107.47 hr & 91.42 hr while the clearance was 113.02 hr &119.0 hr for the group receiving ImAZM and IrAZM, respectively. No significant differences were observed in other PK parameters, areas under the concentration time curves for the groups were almost identical. CONCLUSION: According to the results, there were no significant differences between the PK parameters of ImAZM and IrAZM products. It may be concluded that different doses of AZM have relatively similar PK parameters among the healthy participants.
format Online
Article
Text
id pubmed-5153517
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Babol University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-51535172016-12-20 The HPLC assay of concentration of azithromycin from two different manufacturers in gingival crevicular fluid (GCF) Khosravi-Samani, Mahmoud Dehshiri, Khashayar Kazemi, Sohrab Shiran, Mohamadreza Mohgadamnia, Ali-Akbar Caspian J Intern Med Original Article BACKGROUND: Azithromycin (AZM) is used in periodontal infections. The present study compared gingival crevicular fluid concentration of azithromycin of two pharmaceutical companies through the HPLC method. METHODS: Two groups (n=15) of healthy volunteers participated in this study. The first group received an imported azithromycin (ImAZM) tablet (250 mg, PO) and the second group received an azithromycin tablet (250 mg PO) manufactured by an Iranian pharmaceutical company (IrAZM). Intrasulcular paper points (#30) were used in inter-proximal areas of molars and canines to collect gingival crevicular fluid samples at 6, 12, 36, 84 and 156 hours after drug administration. RESULTS: The maximum concentration of AZM in gingival crevicular fluid was detected in each group 36 hour after administration. The concentration levels for the participants receiving ImAZM and IrAZM were 14.38±5.75 and 12.64±3.53 ng/mL, respectively. The pharmacokinetic (PK) modeling data showed half-life of AZM was 107.47 hr & 91.42 hr while the clearance was 113.02 hr &119.0 hr for the group receiving ImAZM and IrAZM, respectively. No significant differences were observed in other PK parameters, areas under the concentration time curves for the groups were almost identical. CONCLUSION: According to the results, there were no significant differences between the PK parameters of ImAZM and IrAZM products. It may be concluded that different doses of AZM have relatively similar PK parameters among the healthy participants. Babol University of Medical Sciences 2016 /pmc/articles/PMC5153517/ /pubmed/27999643 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Khosravi-Samani, Mahmoud
Dehshiri, Khashayar
Kazemi, Sohrab
Shiran, Mohamadreza
Mohgadamnia, Ali-Akbar
The HPLC assay of concentration of azithromycin from two different manufacturers in gingival crevicular fluid (GCF)
title The HPLC assay of concentration of azithromycin from two different manufacturers in gingival crevicular fluid (GCF)
title_full The HPLC assay of concentration of azithromycin from two different manufacturers in gingival crevicular fluid (GCF)
title_fullStr The HPLC assay of concentration of azithromycin from two different manufacturers in gingival crevicular fluid (GCF)
title_full_unstemmed The HPLC assay of concentration of azithromycin from two different manufacturers in gingival crevicular fluid (GCF)
title_short The HPLC assay of concentration of azithromycin from two different manufacturers in gingival crevicular fluid (GCF)
title_sort hplc assay of concentration of azithromycin from two different manufacturers in gingival crevicular fluid (gcf)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153517/
https://www.ncbi.nlm.nih.gov/pubmed/27999643
work_keys_str_mv AT khosravisamanimahmoud thehplcassayofconcentrationofazithromycinfromtwodifferentmanufacturersingingivalcrevicularfluidgcf
AT dehshirikhashayar thehplcassayofconcentrationofazithromycinfromtwodifferentmanufacturersingingivalcrevicularfluidgcf
AT kazemisohrab thehplcassayofconcentrationofazithromycinfromtwodifferentmanufacturersingingivalcrevicularfluidgcf
AT shiranmohamadreza thehplcassayofconcentrationofazithromycinfromtwodifferentmanufacturersingingivalcrevicularfluidgcf
AT mohgadamniaaliakbar thehplcassayofconcentrationofazithromycinfromtwodifferentmanufacturersingingivalcrevicularfluidgcf
AT khosravisamanimahmoud hplcassayofconcentrationofazithromycinfromtwodifferentmanufacturersingingivalcrevicularfluidgcf
AT dehshirikhashayar hplcassayofconcentrationofazithromycinfromtwodifferentmanufacturersingingivalcrevicularfluidgcf
AT kazemisohrab hplcassayofconcentrationofazithromycinfromtwodifferentmanufacturersingingivalcrevicularfluidgcf
AT shiranmohamadreza hplcassayofconcentrationofazithromycinfromtwodifferentmanufacturersingingivalcrevicularfluidgcf
AT mohgadamniaaliakbar hplcassayofconcentrationofazithromycinfromtwodifferentmanufacturersingingivalcrevicularfluidgcf